House committee advances another PBM reform bill that would ban spread pricing

The House Com­mit­tee on Over­sight and Ac­count­abil­i­ty on Tues­day ad­vanced leg­is­la­tion that would ban some com­mon prac­tices of phar­ma­cy ben­e­fit man­agers — the mid­dle­men who ne­go­ti­ate drug prices on be­half of in­sur­ers.

The bill, called the Delink­ing Rev­enue from Un­fair Goug­ing (DRUG) Act, would re­quire cer­tain PBMs that con­tract with a car­ri­er of­fer­ing fed­er­al health ben­e­fits plans to “de-link” the fees they charge in­sur­ers from the price of drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.